Kiniksa Pharmaceuticals, Ltd. Class A Common Stock

KNSA

...

KNSA: Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

Show KNSA Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of KNSA by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by KNSA's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on KNSA's company Twitter account

WallStreetBets

Number of mentions of KNSA in WallStreetBets Daily Discussion

KNSA News

Recent insights relating to KNSA

CNBC Recommendations

Recent picks made for KNSA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in KNSA

Corporate Flights

Flights by private jets registered to KNSA